• HeraMED to pilot its HeraCARE digital maternity solution at Lee Health
• Lee Health is a major US healthcare provider in Southwest Florida
• Pilot includes onboarding pregnant women across prenatal and postpartum care

HeraMED Limited (ASX: HMD), a medical data and technology company pioneering digital maternity care, has announced that its clinical-grade maternity care platform, HeraCARE, will be piloted by a major US Florida-based health system - Lee Health. Lee Health is a ~$3B revenue non-profit health care system with four acute care hospitals, a children's hospital and more than 1,100 employed physicians. It offers the largest network of medical care facilities in Southwest Florida, while being highly respected for its expertise, innovation and quality of care. Lee Health's hospitals consistently rank in the top 1% for overall care in the US, as well as ranking among the best in the nation for eight specialties, including maternity care and women's health, delivering more than 8,000 babies annually. The pilot with Lee Health has been co-designed with HeraMED's teams engaged across clinical, technical, research and executive leadership as a true partnership. The initial rollout will include a pilot kick-off scheduled to begin in December 2025, with key KPIs to be evaluated over the pilot phase to define success, including patient engagement, virtual visits, remote monitoring and EMR integration roadmap. HeraMED's comprehensive package for Lee Health includes HeraCARE kits equipped with HeraBEAT fetal heart rate monitors and connected blood pressure cuffs for advanced remote monitoring of expectant mothers. Upon successful completion of this pilot, HeraMED expects to implement commercial pricing and expand the deployment with Lee Health to support the phase 2 scale-up to onboard 2,000 pregnancies managed by Lee Health annually.

The pilot is valued at USD $115,000, encompassing implementation, logistics, patient onboarding, and ongoing technical support, and will be included in the phase 2 deployment upon successful completion of the pilot.

HeraMED will provide further updates to the market as implementation progresses and achieving key milestones in the pilot program.